Genetics, pathogenesis and clinical interventions in type 1 diabetes
Top Cited Papers
- 1 April 2010
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature
- Vol. 464 (7293), 1293-1300
- https://doi.org/10.1038/nature08933
Abstract
The clinical picture of type 1 diabetes — a progressive loss of pancreatic β-cell function and a requirement for daily insulin treatment — has been apparent for over a century but the precise nature of the disease progression continues to emerge. Recent progress towards understanding the pathogenetics and genetics of diabetes has been rapid, thanks to extensive research in rodent models and in diabetes patients. A review by Jeffrey Bluestone, Kevan Herold and George Eisenbarth recaps some of the major developments of the past decade and reports on the exciting new clinical interventions that are now being tested, some with the potential to be adapted for use in autoimmune diseases other than diabetes. Type 1 diabetes is an autoimmune disorder afflicting millions of people worldwide. Once diagnosed, patients require lifelong insulin treatment and can experience numerous disease-associated complications. The last decade has seen tremendous advances in elucidating the causes and treatment of the disease based on extensive research both in rodent models of spontaneous diabetes and in humans. Integrating these advances has led to the recognition that the balance between regulatory and effector T cells determines disease risk, timing of disease activation, and disease tempo. Here we describe current progress, the challenges ahead and the new interventions that are being tested to address the unmet need for preventative or curative therapies.Keywords
This publication has 90 references indexed in Scilit:
- AIRE in the thymus and beyondCurrent Opinion in Immunology, 2009
- How Punctual Ablation of Regulatory T Cells Unleashes an Autoimmune Lesion within the Pancreatic IsletsImmunity, 2009
- T Cell Islet Accumulation in Type 1 Diabetes Is a Tightly Regulated, Cell-Autonomous EventImmunity, 2009
- Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 yearsClinical Immunology, 2009
- Extracellular redox modulation by regulatory T cellsNature Chemical Biology, 2009
- Normalization of obesity-associated insulin resistance through immunotherapyNature Medicine, 2009
- Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivoNature Immunology, 2009
- Innate immunity and intestinal microbiota in the development of Type 1 diabetesNature, 2008
- Central Role of Defective Interleukin-2 Production in the Triggering of Islet Autoimmune DestructionImmunity, 2008
- The Foxp3+ regulatory T cell: a jack of all trades, master of regulationNature Immunology, 2008